MedTrace Logo

A Longitudinal Observational Follow-up of the PRECEPT Study Cohort

NCT00605163 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 530

Last updated 2008-03-28

No results posted yet for this study

Summary

The purpose of this study is to longitudinally follow consenting clinical trial participants who participated in PRECEPT (A Randomized, Double Blind, Placebo Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP 1347 in Patients With Early Parkinson's Disease). The study will assess the clinical and imaging outcomes relevant to the natural history of Parkinson's disease (PD), as well as determine early biomarkers of the disease.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Parkinson's Disease Foundation

    collaborator OTHER

  • United States Department of Defense

    collaborator FED

  • The Parkinson Study Group

    lead NETWORK

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2010-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00605163 on ClinicalTrials.gov